WO2022033573A1 - 一种突变型羊传染性脓疱皮炎病毒及其用途 - Google Patents
一种突变型羊传染性脓疱皮炎病毒及其用途 Download PDFInfo
- Publication number
- WO2022033573A1 WO2022033573A1 PCT/CN2021/112408 CN2021112408W WO2022033573A1 WO 2022033573 A1 WO2022033573 A1 WO 2022033573A1 CN 2021112408 W CN2021112408 W CN 2021112408W WO 2022033573 A1 WO2022033573 A1 WO 2022033573A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gene
- virus
- cancer
- orfv112
- orfv111
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title claims abstract description 213
- 208000015181 infectious disease Diseases 0.000 title claims abstract description 54
- 201000004624 Dermatitis Diseases 0.000 title claims abstract description 49
- 230000002458 infectious effect Effects 0.000 title claims abstract description 49
- 241000283898 Ovis Species 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 112
- 201000011510 cancer Diseases 0.000 claims abstract description 36
- 108090000623 proteins and genes Proteins 0.000 claims description 344
- 102000004169 proteins and genes Human genes 0.000 claims description 96
- 238000012217 deletion Methods 0.000 claims description 65
- 230000037430 deletion Effects 0.000 claims description 65
- 238000000034 method Methods 0.000 claims description 59
- 230000014509 gene expression Effects 0.000 claims description 36
- 241001494479 Pecora Species 0.000 claims description 26
- 230000000694 effects Effects 0.000 claims description 21
- 230000036961 partial effect Effects 0.000 claims description 19
- 201000001441 melanoma Diseases 0.000 claims description 13
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 10
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 10
- 201000010881 cervical cancer Diseases 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 206010005003 Bladder cancer Diseases 0.000 claims description 9
- 206010009944 Colon cancer Diseases 0.000 claims description 9
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 9
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- 150000007523 nucleic acids Chemical class 0.000 claims description 8
- 206010033128 Ovarian cancer Diseases 0.000 claims description 7
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 7
- 201000007270 liver cancer Diseases 0.000 claims description 7
- 208000014018 liver neoplasm Diseases 0.000 claims description 7
- 108020004707 nucleic acids Proteins 0.000 claims description 7
- 102000039446 nucleic acids Human genes 0.000 claims description 7
- 230000002601 intratumoral effect Effects 0.000 claims description 6
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 5
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 5
- 206010060862 Prostate cancer Diseases 0.000 claims description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 5
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 5
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 5
- 201000004101 esophageal cancer Diseases 0.000 claims description 5
- 206010017758 gastric cancer Diseases 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 5
- 201000011549 stomach cancer Diseases 0.000 claims description 5
- 208000013077 thyroid gland carcinoma Diseases 0.000 claims description 5
- 206010046766 uterine cancer Diseases 0.000 claims description 5
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 230000010076 replication Effects 0.000 claims description 4
- 230000001131 transforming effect Effects 0.000 claims description 4
- 102000003945 NF-kappa B Human genes 0.000 claims description 3
- 108010057466 NF-kappa B Proteins 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 3
- 238000007920 subcutaneous administration Methods 0.000 claims description 3
- 238000013518 transcription Methods 0.000 claims description 3
- 230000035897 transcription Effects 0.000 claims description 3
- -1 transdermal patch Substances 0.000 claims description 3
- 238000013519 translation Methods 0.000 claims description 3
- 108010011219 dUTP pyrophosphatase Proteins 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000007912 intraperitoneal administration Methods 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 230000000174 oncolytic effect Effects 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 102100023933 Deoxyuridine 5'-triphosphate nucleotidohydrolase, mitochondrial Human genes 0.000 claims 1
- 206010055006 Pancreatic sarcoma Diseases 0.000 claims 1
- 201000002526 pancreas sarcoma Diseases 0.000 claims 1
- 101000623261 Trypanosoma brucei brucei Uncharacterized 25.6 kDa protein in aldolase locus Proteins 0.000 abstract description 124
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 98
- 108091026890 Coding region Proteins 0.000 description 36
- 239000000047 product Substances 0.000 description 24
- 230000002950 deficient Effects 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 20
- 239000002773 nucleotide Substances 0.000 description 18
- 125000003729 nucleotide group Chemical group 0.000 description 18
- 230000003612 virological effect Effects 0.000 description 18
- 244000309459 oncolytic virus Species 0.000 description 15
- 241000894007 species Species 0.000 description 14
- 230000009467 reduction Effects 0.000 description 13
- 108091092724 Noncoding DNA Proteins 0.000 description 11
- 238000001962 electrophoresis Methods 0.000 description 11
- 239000002953 phosphate buffered saline Substances 0.000 description 11
- 108091028043 Nucleic acid sequence Proteins 0.000 description 10
- 239000013612 plasmid Substances 0.000 description 10
- 238000012163 sequencing technique Methods 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 241001529936 Murinae Species 0.000 description 9
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 8
- 108091036066 Three prime untranslated region Proteins 0.000 description 8
- 230000000259 anti-tumor effect Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000001823 molecular biology technique Methods 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 241000700639 Parapoxvirus Species 0.000 description 7
- 238000010171 animal model Methods 0.000 description 7
- 230000002238 attenuated effect Effects 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000011740 C57BL/6 mouse Methods 0.000 description 6
- 241000282552 Chlorocebus aethiops Species 0.000 description 6
- 108700026244 Open Reading Frames Proteins 0.000 description 6
- 125000003275 alpha amino acid group Chemical group 0.000 description 6
- 230000003321 amplification Effects 0.000 description 6
- 238000011081 inoculation Methods 0.000 description 6
- 210000003292 kidney cell Anatomy 0.000 description 6
- 238000003199 nucleic acid amplification method Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 101710172503 Chemokine-binding protein Proteins 0.000 description 5
- 108020005004 Guide RNA Proteins 0.000 description 5
- 108091029795 Intergenic region Proteins 0.000 description 5
- 101710163270 Nuclease Proteins 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 238000000540 analysis of variance Methods 0.000 description 5
- 102000027005 chemokine binding proteins Human genes 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 238000013401 experimental design Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000012224 gene deletion Methods 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000013600 plasmid vector Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 241000283707 Capra Species 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 4
- 206010039491 Sarcoma Diseases 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 208000029742 colonic neoplasm Diseases 0.000 description 4
- 238000001502 gel electrophoresis Methods 0.000 description 4
- 238000010362 genome editing Methods 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 210000000822 natural killer cell Anatomy 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- 230000029812 viral genome replication Effects 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 208000031648 Body Weight Changes Diseases 0.000 description 3
- 238000012270 DNA recombination Methods 0.000 description 3
- 206010061818 Disease progression Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 102000003814 Interleukin-10 Human genes 0.000 description 3
- 108090000174 Interleukin-10 Proteins 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 3
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000004579 body weight change Effects 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 230000001627 detrimental effect Effects 0.000 description 3
- 230000005750 disease progression Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 3
- 238000003209 gene knockout Methods 0.000 description 3
- 230000030279 gene silencing Effects 0.000 description 3
- 230000010005 growth-factor like effect Effects 0.000 description 3
- 230000006801 homologous recombination Effects 0.000 description 3
- 238000002744 homologous recombination Methods 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 229940076144 interleukin-10 Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 230000002100 tumorsuppressive effect Effects 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 230000001018 virulence Effects 0.000 description 3
- MXHRCPNRJAMMIM-SHYZEUOFSA-N 2'-deoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-SHYZEUOFSA-N 0.000 description 2
- NOIIUHRQUVNIDD-UHFFFAOYSA-N 3-[[oxo(pyridin-4-yl)methyl]hydrazo]-N-(phenylmethyl)propanamide Chemical compound C=1C=CC=CC=1CNC(=O)CCNNC(=O)C1=CC=NC=C1 NOIIUHRQUVNIDD-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 238000011729 BALB/c nude mouse Methods 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000282567 Macaca fascicularis Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000700635 Orf virus Species 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 241000700625 Poxviridae Species 0.000 description 2
- 108010009413 Pyrophosphatases Proteins 0.000 description 2
- 102000009609 Pyrophosphatases Human genes 0.000 description 2
- 206010037888 Rash pustular Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000003560 cancer drug Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- MXHRCPNRJAMMIM-UHFFFAOYSA-N desoxyuridine Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 101150097231 eg gene Proteins 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 238000007481 next generation sequencing Methods 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 238000000734 protein sequencing Methods 0.000 description 2
- 208000029561 pustule Diseases 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000007480 sanger sequencing Methods 0.000 description 2
- 239000013605 shuttle vector Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000012536 storage buffer Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 230000007923 virulence factor Effects 0.000 description 2
- 239000000304 virulence factor Substances 0.000 description 2
- 101150110633 112 gene Proteins 0.000 description 1
- 101100269322 Arabidopsis thaliana AFC2 gene Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000621124 Bovine papular stomatitis virus Species 0.000 description 1
- 108091033409 CRISPR Proteins 0.000 description 1
- 206010007269 Carcinogenicity Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 101150091263 E3L gene Proteins 0.000 description 1
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 1
- 101000651211 Homo sapiens Transcription factor PU.1 Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- OEMCLQLAWYKPRK-OQLLNIDSSA-N N-[(E)-(5-bromo-2-hydroxyphenyl)methylideneamino]benzenesulfonamide Chemical compound Oc1ccc(Br)cc1\C=N\NS(=O)(=O)c2ccccc2 OEMCLQLAWYKPRK-OQLLNIDSSA-N 0.000 description 1
- 230000006051 NK cell activation Effects 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 241000621122 Parapoxvirus of red deer in New Zealand Species 0.000 description 1
- 101000836070 Rattus norvegicus Serine protease inhibitor A3L Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 241001123657 Seal parapoxvirus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 102100027654 Transcription factor PU.1 Human genes 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 101900001372 Vaccinia virus RNA-binding protein E3 Proteins 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 229940031567 attenuated vaccine Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 231100000260 carcinogenicity Toxicity 0.000 description 1
- 230000007670 carcinogenicity Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000012094 cell viability reagent Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000013377 clone selection method Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 210000000448 cultured tumor cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 231100000409 cytocidal Toxicity 0.000 description 1
- 230000000445 cytocidal effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000005549 deoxyribonucleoside Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 229940083538 smallpox vaccine Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000009121 systemic therapy Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 239000005723 virus inoculator Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24211—Parapoxvirus, e.g. Orf virus
- C12N2710/24221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24211—Parapoxvirus, e.g. Orf virus
- C12N2710/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24211—Parapoxvirus, e.g. Orf virus
- C12N2710/24232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24211—Parapoxvirus, e.g. Orf virus
- C12N2710/24271—Demonstrated in vivo effect
Definitions
- the invention relates to the field of biotechnology, in particular to the use of a mutant ovine infectious pustular dermatitis virus (ORFV) and a pharmaceutical composition thereof in cancer treatment.
- ORFV ovine infectious pustular dermatitis virus
- Sheep infectious pustular dermatitis virus belongs to the genus Parapoxvirus in the Poxviridae family.
- the genus also includes bovine papular stomatitis virus, pseudovaccinia virus, parapox virus of red deer in New Zealand, and Sealpox virus.
- Patent CN 104017776 B discloses an attenuated ORFV obtained after separation and cell subculture, which is used for vaccine development.
- Patent CN 108026542 A describes the use of virus strain D1701 to construct a recombinant ORFV vector to express viral antigens, tumor antigens, etc. for the preparation of vaccines.
- Oncolytic viral therapy is a systemic therapy that uses naturally occurring or engineered viruses to treat tumors. Those specific gene mutations that originally promote the proliferation and survival of tumor cells can also promote the growth of viruses with lytic function in them, which is one of the reasons why oncolytic viruses precisely attack tumor cells [1, 2, 3] .
- Oncolytic viruses after infecting cancer cells can promote the lysis and death of cancer cells at appropriate time points in the virus life cycle, and release infectious virus particles to further infect surrounding uninfected cancer cells.
- the neoantigen (neoantigen) released by the lysis of cancer cells activates the immune system, thereby making a follow-up attack on cancer [4] .
- ORFV virus is a double-stranded DNA virus with a length of about 134-139kb. Virus particles are 230-280nm long and 150-200nm wide, and are elliptical coil-like [6] .
- ORFV virus has the following characteristics: 1) Similar to members of the Poxviridae family of the same family, ORFV virus only replicates in the cytoplasm of the host cell, does not enter the nucleus, and thus will not integrate into the genome of the host cell, so it is safe, The probability of carcinogenicity is extremely low [7, 10] ; 2) It can infect humans through contact with damaged skin and animal infection areas, and produce clinically mild pustules at the infection site (usually fingers), and there are basically no other adverse side effects.
- ORFV strains typically encode about 130-134 genes.
- the currently identified virulence factors mainly include viral interferon inhibitory protein (OVIFNR, ORFV020), chemokine binding protein (CBP, ORFV112), GM-CSF/IL-2 inhibitory protein (GIF, ORFV117), viral interleukin 10 (vIL-10, ORFV127) and vascular endothelial growth factor-like protein (VEGF-like protein, ORFV132) and so on [11] .
- the proteins encoded by these genes can also regulate the body's immune response [13] .
- ORFV002 is a late viral gene, which is located in the nucleus after protein synthesis and inhibits the NF- ⁇ B pathway in the nucleus. It was identified as the first NF- ⁇ B nuclear inhibitor produced by ORFV virus [19] .
- the gene ORFV005 is a hypothetical protein gene, and its mechanism of action is still unclear.
- the gene ORFV007 encodes deoxyuridine pyrophosphatase (duTPase) [15] .
- This protein is an important enzyme in the synthesis of dNTPs (deoxyribonucleoside triphosphates).
- dNTPs deoxyribonucleoside triphosphates
- concentration of dNTPs in normal cells is tightly regulated and thus detrimental to viral replication.
- cancer cells there are higher concentrations of dNTPs, which can promote virus replication [16] .
- the deletion of the ORFV007 gene blocks the replication of the virus in normal cells, but does not affect its amplification in tumor cells, so that the ORFV virus can selectively replicate in cancer cells.
- the gene ORFV111 is a hypothetical protein gene, and its mechanism of action is still unclear.
- CBP protein ORFV112 (chemokine-binding protein, chemokine-binding protein), is about 864 bp long, and its function is to inhibit the antiviral mechanism of immune cells [14] .
- This protein is similar in structure and function to CBP-II proteins of other poxviruses, which can not only inhibit the migration of DC cells to the inflammatory site, but also inhibit the activation of T cells by DC cells.
- NZ-2, NZ-7, D1701, NA1/11 and so on have been published and used for the research of oncolytic virus ORFV virus strains.
- ORFV virus can insert relatively large exogenous DNA fragments, it is generally used as a vector to insert a certain tumor-specific antigen or viral antigen, cytokine, etc., to obtain a genetically recombinant virus for research.
- Patent WO 2012122649A1 discloses a recombinant OFRV virus (insert vaccinia virus E3L gene) that infects tumor cells containing specific host range genes (SPI-1, K1L, C7L, B5R, p28/N1R, E3L, etc.) for cancer drug development.
- Patent CN 108220251 A discloses a recombinant infectious pustular oncolytic virus and its preparation method and application, which mainly include knocking out the ORFV132 (VEGF) gene of the NA1/11 strain and inserting a P53-EGFP fusion protein at the same position Genes for cancer drug development.
- the strains described in the above two patents have neither reported the deletion of the ORFV112 gene nor the deletion of the ORFV007 gene.
- a mutant sheep transmissible pustular dermatitis virus characterized by the deletion of the functional expression product of the gene ORFV112 and/or the gene ORFV111, wherein the deletion of the functional expression product is caused by the gene ORFV112 and/or the gene encoding CBP.
- the inventors unexpectedly found that the complete deletion or partial deletion of the ORFV 112 gene and/or the ORFV 111 gene can significantly enhance the anti-tumor effect of the virus.
- the genome sequence of the mutant sheep infectious pustular dermatitis virus was compared with the genome sequences of all other published ORFV virus strains, and it was found that the ORFV 007 dUTPase gene of the mutant sheep infectious pustular dermatitis virus appeared. Completely missing. Further, the above comparison also confirmed that the ORFV002 and ORFV005 genes of the ovine infectious pustular dermatitis virus were completely deleted.
- the mutant ovine infectious pustular dermatitis virus of the present disclosure has a guiding role in the development of anti-tumor drugs for this type of virus.
- the inventors unexpectedly discovered that the complete deletion or partial deletion of the gene ORFV112 (encoding the CBP protein) and/or the gene ORFV111 (encoding a hypothetical protein, hereinafter referred to as the hypothetical protein 111) (especially the 5' partial deletion of the gene ORFV112 and the gene ORFV111) Deletion of the 3' part of ovine infectious pustular dermatitis virus) enhances the antitumor activity of ovine infectious pustular dermatitis virus. Further, the inventors also unexpectedly found that the gene ORFV007 of the mutant ovine infectious pustular dermatitis virus is completely deleted.
- Infectious pustular dermatitis virus of sheep with functional CBP protein and/or hypothetical protein 111 deletion can be detected by conventional molecular biology methods (eg molecular cloning, DNA recombination, homologous recombination, PCR, restriction nucleases, gene knockout, silencing etc.) or emerging molecular biology methods (such as gene editing, etc.).
- conventional molecular biology methods eg molecular cloning, DNA recombination, homologous recombination, PCR, restriction nucleases, gene knockout, silencing etc.
- emerging molecular biology methods such as gene editing, etc.
- the present invention provides a mutant sheep transmissible pustular dermatitis virus characterized by deletion of the functional expression product of gene ORFV112 and/or gene ORFV111.
- the deletion of the functional expression product of the gene ORFV112 results from a complete or partial (e.g., 5' part or 3' part, especially the 5' part) deletion of the gene ORFV112.
- the mature sequence of the expression product of the gene ORFV112 is shown in SEQ ID NO:2.
- the complete sequence of the gene ORFV112 is shown in SEQ ID NO:3.
- SEQ ID NO:3 is completely deleted.
- SEQ ID NO:3 is partially deleted, eg, 1-1161, 1-1140, 1-538, 539-1139, or 1141-1160 5' bases are deleted.
- the partially deleted gene ORFV112 is shown in SEQ ID NO:4 or SEQ ID NO:57.
- the deletion of the functional expression product of the gene ORFV111 results from a complete or partial (e.g., 5' part or 3' part, especially 3' part) deletion of the gene ORFV111.
- the sequence of the expression product of the gene ORFV111 is shown in SEQ ID NO:58.
- the complete sequence of gene ORFV111 is set forth in SEQ ID NO:59.
- SEQ ID NO:59 is completely deleted. In one embodiment, SEQ ID NO:59 is partially deleted, eg, 1-793, 1-309, or 310-792 3' bases are deleted. In one embodiment, the partially deleted gene ORFV111 is shown in SEQ ID NO:60. In one embodiment, SEQ ID NO:3 and SEQ ID NO:59 are completely deleted. In one embodiment, the expression product is a protein and/or a nucleic acid (especially a functional nucleic acid). In one embodiment, the present invention provides the genome of the virus.
- the present invention provides a method for transforming ovine infectious pustular dermatitis virus, which comprises reducing or eliminating the expression and/or activity of the expression product of gene ORFV112 and/or gene ORFV111.
- the method comprises deletion of the gene ORFV112 in whole or in part (e.g., the 5' part or the 3' part, especially the 5' part).
- the mature sequence of the expression product of the gene ORFV112 is shown in SEQ ID NO:2.
- the complete sequence of the gene ORFV112 is shown in SEQ ID NO:3.
- the method comprises deleting SEQ ID NO:3 completely.
- the method comprises a partial deletion of SEQ ID NO: 3, such as deletion of 1-1161, 1-1140, 1-538, 539-1139 or 1141-1160 5' bases.
- the method produces the partially deleted gene ORFV112 as set forth in SEQ ID NO:4 or SEQ ID NO:57.
- the method comprises deletion of the gene ORFV111 in whole or in part (e.g. in the 5' part or the 3' part, especially the 3' part).
- the sequence of the expression product of the gene ORFV111 is shown in SEQ ID NO:58.
- the complete sequence of gene ORFV111 is set forth in SEQ ID NO:59.
- the method comprises deleting SEQ ID NO:59 completely.
- the method comprises a partial deletion of SEQ ID NO: 59, such as deletion of 1-793, 1-309 or 310-792 3' bases.
- the method produces a partially deleted gene ORFV111 as set forth in SEQ ID NO:60.
- the method comprises the complete deletion of SEQ ID NO:3 and SEQ ID NO:59.
- expression is transcription and/or translation.
- the present invention provides a virus obtained by the method. In one embodiment, the present invention provides the genome of the virus.
- the methods of the present invention can be performed by conventional molecular biology techniques (eg molecular cloning, DNA recombination, homologous recombination, PCR, restriction nucleases, gene knockout, silencing, etc.) or emerging molecular biology techniques (eg gene editing, etc.) .
- conventional molecular biology techniques eg molecular cloning, DNA recombination, homologous recombination, PCR, restriction nucleases, gene knockout, silencing, etc.
- emerging molecular biology techniques eg gene editing, etc.
- the present invention provides a method for identifying the mutant ovine infectious pustular dermatitis virus and/or its genome, in particular for detecting the (presence or sequence) of gene ORFV112 and/or gene ORFV111 and/or its expression Methods of product (presence and/or activity).
- the methods of the present invention can be performed by conventional molecular biology techniques (eg, activity assays, hybridization (eg, Southern, Northern, or Western)), which detect the presence and/or activity of proteins and/or nucleic acids and/or sequences, Restriction endonucleases, PCR, electrophoresis (eg, gel electrophoresis, including protein electrophoresis and nucleic acid electrophoresis, including agarose electrophoresis and PAGE electrophoresis, including reducing and non-reducing electrophoresis), sequencing (including protein sequencing and nucleic acid sequencing), etc. ) or emerging molecular biology techniques (such as next-generation sequencing, etc.).
- conventional molecular biology techniques eg, activity assays, hybridization (eg, Southern, Northern, or Western)
- electrophoresis eg, gel electrophoresis, including protein electrophoresis and nucleic acid electrophoresis, including agarose electrophoresis and PAGE electrophor
- the present invention provides methods for detecting the integrity of the gene ORFV112 and/or the gene ORFV111.
- the method is performed by PCR and gel electrophoresis.
- the method can be performed by hybridization or sequencing.
- the present invention provides a method of treating cancer in a subject using the mutant ovine infectious pustular dermatitis virus and/or its genome.
- the present disclosure provides use of the mutant ovine infectious pustular dermatitis virus and/or its genome for treating cancer in a subject.
- the present disclosure provides use of the mutant ovine infectious pustular dermatitis virus and/or its genome to prepare a medicament for treating cancer in a subject.
- the present disclosure provides the mutant ovine infectious pustular dermatitis virus and/or its genome for use in the treatment of cancer in a subject.
- the present disclosure provides the mutant ovine infectious pustular dermatitis virus and/or its genome for use in the manufacture of a medicament for treating cancer in a subject.
- the cancer is a solid tumor.
- the solid tumor is cervical cancer, bladder cancer, liver cancer, ovarian cancer, melanoma, colorectal cancer, lung cancer, breast cancer, gastric cancer, uterine cancer, head and neck cancer, thyroid cancer, esophageal cancer, prostate cancer , pancreatic cancer, sarcoma, brain tumor, etc.
- the subject is a mammal, including rodents (eg, mice and rats), non-human primates (eg, cynomolgus monkeys), and humans.
- Figure 1 shows the results of agarose gel electrophoresis of PCR products after PCR amplification using ORFV112 gene-specific forward primers and reverse primers (SEQ ID NOs: 5 and 6).
- Sample No. 1 in the figure is the ORFV112 gene deletion virus strain POV-601-1A1
- sample No. 2 is the ORFV112 gene intact virus strain POV-601-3F8, and M is the DNA size marker.
- Figure 2 shows the tumor suppressor effect of the ORFV112 gene deletion virus strains POV-601-1A1 and POV-604-1D1 on the MB49 murine bladder cancer model.
- Figure 3 shows the tumor suppressor effect of ORFV112 gene deletion virus strains POV-601-1A1 and POV-604-1D1, and ORFV112 gene intact virus strain POV-601-3F8 in B16-F10 murine melanoma tumor model.
- Figure 4 shows the effect of POV-601-1A1 virus on the body weight of mice under different doses and administration routes.
- Figure 5 shows the changes of the mouse immune system in the human C-33A cervical cancer bilateral tumor model after administration of POV-601-1A1 virus strain.
- the square represents the result of intratumoral administration on the right side
- the circle represents the result of no administration on the left side.
- intratumoral administration the activation ratio of CD45 + and NK cells in the tumor was increased.
- Fig. 5C shows the activation of NK cells in blood, and the ratio of activation of NK cells was increased by intravenous administration.
- Figure 6 shows the alignment of the complete nucleotide sequence of the gene ORFV112 of the present invention with an example of a partially deleted sequence.
- Figure 7 shows the alignment of the complete sequence of the CBP protein of the present invention with the complete sequence of the CBP protein of other parapoxvirus strains.
- 3F8 means POV-601-3F8Strain
- B029 means ORFV Strain B029
- GO means ORFV Strain GO
- NA11 means ORFV Strain NA1/11
- NZ2 means ORFV Strain NZ2
- NA17 means ORFV Strain NA17
- OV-SA00 means ORFV Strain OV-SA00
- O-IA82 means ORFV Strain OV-IA82
- SJ1 means ORFV Strain SJ1
- SY17 means ORFV Strain SY17
- OV-NH3_12 means ORFV Strain OV-HN3/12
- NP means ORFV Strain NP
- YX means ORFV Strain YX.
- Fig. 8 shows the alignment of the complete sequence of ORFV112 gene of the present invention with the complete sequence of ORFV112 gene of other parapoxvirus strains.
- 3F8 means POV-601-3F8Strain
- B029 means ORFV Strain B029
- GO means ORFV Strain GO
- NA11 means ORFV Strain NA1/11
- NZ2 means ORFV Strain NZ2
- NA17 means ORFV Strain NA17
- OV-SA00 means ORFV Strain OV-SA00
- O-IA82 means ORFV Strain OV-IA82
- SJ1 means ORFV Strain SJ1
- SY17 means ORFV Strain SY17
- OV-NH3_12 means ORFV Strain OV-HN3/12
- NP means ORFV Strain NP
- YX means ORFV Strain YX.
- Figure 9 shows the alignment of the complete nucleotide sequence of the gene ORFV111 of the present invention with an example of a partially deleted sequence.
- Figure 10 shows the alignment of the hypothetical protein 111 complete sequence of the present invention with the hypothetical protein 111 complete sequence of other parapoxvirus strains.
- POV-601-3F8 means POV-601-3F8Strain
- B029 means ORFV Strain B029
- GO means ORFV Strain GO
- NA11 means ORFV Strain NA1/11
- NZ2 means ORFV Strain NZ2
- NA17 means ORFV Strain NA17
- OV-SA00 means ORFV Strain OV-SA00
- “OV-IA82” means ORFV Strain OV-IA82
- SJ1 means ORFV Strain SJ1
- SY17 means ORFV Strain SY17
- OV- NH3_12 means ORFV Strain OV-HN3/12
- NP means ORFV Strain NP
- YX means ORFV Strain YX.
- Figure 11 shows the alignment of the complete sequence of ORFV111 gene of the present invention with the complete sequence of ORFV111 gene of other parapoxvirus strains.
- POV-601-3F8 means POV-601-3F8 Strain
- B029 means ORFV Strain B029
- GO means ORFV Strain GO
- NA11 means ORFV Strain NA1/11
- NZ2 means ORFV Strain NZ2
- NA17 means ORFV Strain NA17
- OV-SA00 means ORFV Strain OV-SA00
- O-IA82 means ORFV Strain OV-IA82
- SJ1 means ORFV Strain SJ1
- SY17 means ORFV Strain SY17
- OV -NH3_12
- NP means ORFV Strain OV-HN3/12
- NP means ORFV Strain NP
- YX means ORFV Strain YX.
- Fig. 12 shows the alignment of the complete amino acid sequence of the gene ORFV111 of the present invention and the example of the partial deletion sequence
- Fig. 13 shows the alignment of the complete amino acid sequence of the gene ORFV112 of the present invention and the example of the partial deletion sequence
- Figure 14 shows the tumor suppressor effect of the ORFV112 gene deletion virus strain POV-601-1A1 and the ORFV112 gene complete virus strain POV-601-3F8 in the CT-26 mouse colon cancer tumor model.
- Figure 15 shows the tumor suppressive effect of POV-601-1A1 and construct v611a in the B16-F10 murine melanoma tumor model.
- Figure 16 shows the tumor suppressive effect of POV-601-1A1 and constructs v615a and v616a in a B16-F10 murine melanoma tumor model.
- Figure 17 shows the tumor suppressive effect of POV-601-1A1 and constructs v617a and v618a in a B16-F10 murine melanoma tumor model.
- the invention discloses the use of a mutant sheep infectious pustular dermatitis virus (ORFV) and its medicinal composition in cancer treatment.
- ORFV sheep infectious pustular dermatitis virus
- the virulence genes of wild-type aphthous goat infectious pustular dermatitis virus mainly include OVIFNR (orf virus interferon resistance gene, interferon inhibitory protein), CBP (chemokine-binding protein, chemokine-binding protein), GIF (GM-CSF/IL-2 inhibitory protein, GM-CSF/IL-2 inhibitory protein), vIL-10 (viral interleukin 10, viral interleukin 10) and VEGF-like protein (vascular endothelial growth factor like protein, vascular Endothelial growth factor-like protein) and so on [11,13] .
- OVIFNR orf virus interferon resistance gene, interferon inhibitory protein
- CBP chemokine-binding protein, chemokine-binding protein
- GIF GM-CSF/IL-2 inhibitory protein
- vIL-10 viral interleukin 10
- VEGF-like protein vascular endothelial growth factor like protein, vascular Endothelial growth
- Attenuated strains can generally be obtained by removing a certain virulence factor gene of the virus using molecular and/or cellular biological methods.
- a method for obtaining an attenuated strain is disclosed by deleting the virulence gene OVIFNR of the aphtha virus strain SHZ1 to achieve rapid reduction of its virulence, which is used for preparing attenuated vaccines.
- the mutant sheep infectious pustular dermatitis virus disclosed in the present invention is obtained by modifying and screening the original POV-601 virus strain deposited in the China Center for Type Culture Collection (CCTCC) (accession number: V201713).
- the inventor designed specific primers for the ORFV112 gene according to the literature [17] .
- the forward primer (SEQ ID NO:5) was designed on the coding region of the ORFV111 gene
- the reverse primer (SEQ ID NO:6) was designed on the coding region of the ORFV112 gene, thereby establishing a PCR-based molecule Biological identification technology to identify the integrity of the ORFV112 gene of the POV-601 attenuated strain.
- African green monkey kidney cells CV-1 were infected with the original POV-601 virus strain, and the virus-infected cells were collected, and single-cell sorting and culture expansion were performed by flow cytometry.
- the viral genomic DNA was extracted from the amplified, virus-infected cells, and the ORFV virus attenuated strain with the partial deletion of the ORFV112 gene was obtained by the established molecular biology identification technology, Designated POV-601-1A1.
- the ORFV112 gene coding region sequence of this strain 312 bases are missing at the 5' end, 552 bases remain, and 72 bases remain in the non-coding region at the 3' end, for a total of 624 bases, see SEQ ID NO: 4.
- a virus strain POV-601-3F8 with a complete ORFV112 gene was also obtained, and its coding region and non-coding region totaled 1162 bases.
- the complete sequence of the ORFV112 gene is shown in SEQ ID NO:3.
- the inventors further artificially used gene editing means for the POV-601-1A1 virus strain, trying to knock out all the remaining coding regions of the gene ORFV112 of the virus strain.
- the remaining coding region of the gene ORFV112 was completely knocked out (only 22 bases of the 3'-end non-coding region remained, see sequence SEQ ID NO: 57), and confirmed by DNA sequencing.
- the virus strain thus obtained was named POV-604-1D1.
- the attenuated strain also had better anti-tumor effect than the virus strain POV-601-3F8 with complete ORFV112 gene.
- any method that leads to the inability to express CBP protein such as knocking out or changing certain sequences in the coding region and non-coding region of the gene ORFV112, can also achieve the same effect.
- the POV-601-1A1 virus strain was deposited in the China Collection of Type Cultures (CCTCC) (Wuhan) on May 19, 2020 in accordance with the provisions of the Budapest Treaty, and the CCTCC deposit number is V202029.
- CTCC China Collection of Type Cultures
- the mutated aphthous transmissible pustular dermatitis virus of the present disclosure can selectively infect melanoma cells (B16-F10), bladder cancer cells (MB49), liver cancer cells (Hepa1-6), colon cancer cells cells (CT26), human cervical cancer cells (C-33A), human ovarian cancer cells (SK-OV-3), etc., and replicate in them.
- the gene ORFV007 of the mutant aphthous guinea pig infectious dermatitis virus of the present disclosure was unexpectedly found to be completely deleted, while all the aphthous guinea pig infectious pustular dermatitis virus strains that have been published in NCBI, such as NZ -2, NZ-7, D1701, NA1/11 strains, etc., the gene ORFV007 is complete.
- the ORFV007 gene encodes deoxyuridine pyrophosphatase (duTPase). This protein is an important enzyme in dNTP synthesis. In general, the concentration of dNTPs in normal cells is tightly regulated and thus detrimental to viral replication.
- Wild-type ORFV virus can generally be cultured in primary cells of bovine and ovine animal tissue (CN 103952377 A).
- Patent WO2012122649A1 discloses for the first time that the virus can be propagated and expanded in human cervical cancer cell Hela.
- the present invention discloses a preparation method of the mutant aphthous goat infectious pustular dermatitis virus, using a mammalian cell line as the host cell, preferably, using the African green monkey kidney cell CV-1 as the host cell, For viral infection amplification.
- the cancer is any solid tumor cancer.
- the solid tumor cancer types include: cervical cancer, bladder cancer, liver cancer, ovarian cancer, melanoma, colorectal cancer, lung cancer, breast cancer, stomach cancer, uterine cancer, head and neck cancer, thyroid cancer, esophageal cancer, prostate cancer, pancreas cancer Carcinoma, sarcoma, brain tumor, etc.
- the individual is a mammal, including rodents and humans.
- the mechanism by which oncolytic virus inhibits tumor growth can generally be divided into: 1) replicating and expanding in infected tumor cells, lysing cancer cells, and achieving the purpose of oncolysis; 2) after oncolysis, the specific Messages, such as tumor neoantigens, are released, activating the immune system to systematically attack the remaining cancer cells.
- the mutant aphthous ovine infectious pustular dermatitis virus of the present disclosure can effectively activate the autonomous immune system represented by NK cells.
- intratumoral and/or intravenous injection of virus increased the proportion of CD45 + and NK cell activation in tumors and/or blood.
- OV Oncolytic virus, which is an oncolytic virus.
- solid tumor refers to a tumor entity composed of multiple cells to distinguish hematological tumors; it can be cervical cancer, bladder cancer, liver cancer, ovarian cancer, melanoma, colorectal cancer, lung cancer, breast cancer, stomach cancer, uterine cancer, head and neck cancer, Thyroid cancer, esophageal cancer, prostate cancer, pancreatic cancer, sarcoma, brain tumor, etc. Cancer can be in early or late stages.
- continuous cell line a group of cells with special genetic properties, biochemical properties or specific markers obtained from a primary culture or cell line is called a cell line, and a cell line that can be serially passaged is called a continuous cell line cell line.
- CPE cytopathic effect, ie cellular degeneration following infection of cultured cells by a virus.
- CPE cytopathic effect
- sheep infectious pustular dermatitis virus also known as sheep aphthous virus, aphthous virus, ORFV, orf virus, etc., is a pox virus that can cause contagious, epitheliophilic diseases of sheep and goats.
- an effective amount refers to an amount effective at the dose and for the time necessary to achieve the desired therapeutic or prophylactic effect.
- a therapeutically effective amount also refers to an amount in which any toxic or detrimental consequences of the therapeutic agent are outweighed by the therapeutically beneficial effects.
- PBS is phosphate buffer saline, the abbreviation of phosphate buffered saline.
- MOI Multiplicity of Infection, which refers to the ratio (pfu/cell) between the number of virus particles and the total number of target cells during virus infection of cells.
- POV-601-1A1 virus strain “POV” is the abbreviation of "Prajna Oncolytic Virus", which means that the virus strain originated from Suzhou Prajna Biotechnology Co., Ltd.; in the internal experimental records of Suzhou Prajna Biotechnology Co., Ltd. , POV-601-1A1, v601-1A1, v601-p0-1A1 and 1A1, all represent the same strain of virus.
- the virus strain is named "mutant type of ovine infectious pustular dermatitis virus POV-601-1A1" in the CCTCC's deposit registration table, which belongs to the ovine infectious pustular dermatitis virus in the genus Parapoxvirus of the Pox family.
- POV-601-3F8 virus strain “POV” stands for "Prajna Oncolytic Virus", which means that the virus strain originated from Suzhou Prajna Biotechnology Co., Ltd.; in the internal records of Suzhou Prajna Biotechnology Co., Ltd., POV-601- 3F8, v601-3F8, v601-p0-3F8 and 3F8 all represent the same strain of virus.
- POV-604-1D1 virus strain “POV” stands for "Prajna Oncolytic Virus", which means that the virus strain originated from Suzhou Prajna Biotechnology Co., Ltd.; in the internal records of Suzhou Prajna Biotechnology Co., Ltd., POV-604- 1D1, v604-1D1 and 1D1 all represent the same strain of virus.
- virus storage buffer the preparation method is to draw 500 mL of PBS (ie, phosphate buffer, CORNING, product number: 21-040-CVR), add 1.25 mL of 1M MgCl 2 ⁇ 6H 2 O (Sangon Bioengineering (Shanghai) Co., Ltd.
- the present invention relates to a (native) CBP protein.
- the (native) CBP protein has or comprises at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical full-length sequence or having or comprising as shown in SEQ ID NO: 2 or from the same or similar organism origin (eg, strain, species, genus, family) and at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to it the mature sequence of, or (essentially) consist of.
- the (native) CBP protein has or comprises as set forth in SEQ ID NOs: 31-42 or is derived from the same or similar biological source (e.g. strain, species, genus, family) and has at least 90%, Full-length sequences of 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity, and corresponding mature sequences.
- the present invention also relates to a mutant CBP protein.
- a mutation is an addition, deletion or substitution of one or more amino acid residues, or any combination thereof, relative to the native sequence.
- the function of the mutant CBP protein is reduced or absent.
- the present invention also relates to the reduction or deletion of the expression of CBP proteins (eg, native CBP proteins or mutant CBP proteins).
- CBP proteins eg, native CBP proteins or mutant CBP proteins.
- a reduction is at least a 50%, 60%, 70%, 75%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96% reduction compared to native function and/or expression , 97%, 98%, 99%, up to 100%.
- the present invention relates to a (native) ORFV112 gene.
- the (native) ORFV112 gene encoding has or comprises at least 90%, 91% as set forth in SEQ ID NO: 1 or from the same or similar biological source (e.g.
- the (native) CBP protein has or comprises as set forth in SEQ ID NOs: 31-42 or is derived from the same or similar biological source (e.g. strain, species, genus, family) and has at least 90%, Full-length sequences of 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity, and corresponding mature sequences.
- the present invention relates to a (native) ORFV112 gene
- the (native) ORFV112 gene has or comprises as shown in SEQ ID NO: 3 (or its coding region), encodes the same amino acid sequence, or is derived from the same or Approximate biological origin (eg, strain, species, genus, family) with at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% therewith , 98%, 99% or 100% identical nucleotide sequences, or (substantially) consist of them.
- the (native) ORFV112 gene has or comprises, encodes the same amino acid sequence as set forth in SEQ ID NOs: 43-54 (or coding regions thereof), or is derived from the same or similar biological source (e.g., strain, species, genus, family) with at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100 % identity of nucleotide sequences.
- the present invention also relates to a mutant ORFV112 gene.
- a mutation is an addition, deletion or substitution of one or more bases, or any combination thereof, relative to the native sequence.
- the mutant ORFV112 gene is a completely deleted ORFV112 gene.
- the complete deletion type ORFV112 gene lacks the entire ORFV112 gene.
- the mutant ORFV112 gene is a partially deleted ORFV112 gene.
- the partially deleted ORFV112 gene lacks one or more but not all bases of the ORFV112 gene.
- the partially deleted ORFV112 gene lacks one or more bases of the 5' untranslated region, the coding region and/or the 3' untranslated region, or any combination thereof.
- the partially deleted ORFV112 gene is a 5'-deleted ORFV112 gene, that is, one or more bases at the 5' end are deleted, eg, the entire or part of the 5' untranslated region is deleted, the entire 5' untranslated region is deleted and all or part of the coding region, or deletion of the entire 5' untranslated region, the entire coding region and all or part of the 3' untranslated region.
- the ORFV112 gene is deleted upstream (into the ORFV111/112 intergenic region, if present, and/or the ORFV111 gene, particularly the 3' end) and/or downstream (into the ORFV112/113 intergenic region, if If present, and/or the ORFV113 gene, especially the 5' end) extension.
- the partially deleted ORFV112 gene lacks SEQ ID NO: 3 One or more bases of the sequence shown in ID NO: 3, eg, 1-1161 bases.
- the native ORFV112 gene has or comprises or (essentially) consists of the nucleotide sequence shown in SEQ ID NO: 3 (or its coding region)
- the 5'-terminal deletion ORFV112 gene Deletion of one or more bases at the 5' end of the sequence shown in SEQ ID NO: 3, particularly 1-1161, 1-1140, 1-538, 539-1139 or 1141-1160 bases at the 5' end base.
- the 5'-deleted ORFV112 gene has or comprises, or (essentially) consists of, the nucleotide sequence set forth in SEQ ID NO:4 or SEQ ID NO:57 (or its coding region) .
- the native ORFV112 gene has or comprises or (essentially) consists of the nucleotide sequence set forth in SEQ ID NOs: 43-54 (or its coding region)
- the 5'-terminal deletion type The ORFV112 gene deletes one or more bases at the 5' end of the sequences shown in SEQ ID NOs: 43-54, especially one or more of the segments corresponding to 1140 or 538 bases at the 5' end of SEQ ID NO: 3 multiple bases. These deleted genes were unable to express protein due to deletion of the 5' untranslated region and/or start codon.
- the mutant ORFV112 gene of the invention results in reduced or absent functional CBP protein, including reduced or absent expression and/or activity of CBP protein.
- a reduction is at least a 50%, 60%, 70%, 75%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96% reduction compared to native function and/or expression , 97%, 98%, 99%, up to 100%.
- the present invention relates to a (native) hypothetical protein 111.
- the (native) hypothetical protein 111 has or comprises at least 90%, 91% as set forth in SEQ ID NO: 58 or from the same or similar biological source (e.g. strain, species, genus, family) , 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to, or consist of (essentially).
- the (native) hypothetical protein 111 has or comprises at least 90% as set forth in SEQ ID NOs: 61-72 or from the same or similar biological source (eg strain, species, genus, family) , 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical sequences.
- the present invention also relates to a mutant hypothetical protein 111.
- a mutation is an addition, deletion or substitution of one or more amino acid residues, or any combination thereof, relative to the native sequence.
- the function of the mutant hypothetical protein 111 is reduced or absent.
- the invention also relates to the reduction or deletion of the expression of a hypothetical protein 111 (eg, a native hypothetical protein 111 or a mutant hypothetical protein 111).
- a hypothetical protein 111 eg, a native hypothetical protein 111 or a mutant hypothetical protein 111.
- a reduction is at least a 50%, 60%, 70%, 75%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96% reduction compared to native function and/or expression , 97%, 98%, 99%, up to 100%.
- the present invention relates to a (native) ORFV111 gene.
- the (native) ORFV111 gene encoding has or comprises as shown in SEQ ID NO: 58 or is from the same or similar biological source (eg strain, species, genus, family) and has at least 90%, 91% therewith , 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical sequences, or (essentially) a hypothetical protein 111 consisting of them.
- the (native) hypothetical protein 111 has or comprises at least 90% as set forth in SEQ ID NOs: 61-72 or from the same or similar biological source (eg strain, species, genus, family) , 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical sequences.
- the present invention relates to a (native) ORFV111 gene
- the (native) ORFV111 gene has or comprises as shown in SEQ ID NO: 59 (or its coding region), encodes the same amino acid sequence, or is derived from the same or Approximate biological origin (eg, strain, species, genus, family) with at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97% therewith , 98%, 99% or 100% identical nucleotide sequences, or (substantially) consist of them.
- SEQ ID NO:59 has a full length of 794 bases, wherein the 1-28th base is the 5' non-coding region, the 29-568th base is the protein coding region, and the 569-794th base is the 3' non-coding region. coding area.
- the (native) ORFV111 gene has or comprises, encodes the same amino acid sequence as set forth in SEQ ID NOs: 73-84 (or coding regions thereof), or is derived from the same or similar biological source (e.g. strain, species, genus, family) with at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100 % identity of nucleotide sequences.
- the present invention also relates to a mutant ORFV111 gene.
- a mutation is an addition, deletion or substitution of one or more bases, or any combination thereof, relative to the native sequence.
- the mutant ORFV111 gene is a complete deletion of the ORFV111 gene.
- the complete deletion type ORFV111 gene lacks the entire ORFV111 gene.
- the mutant ORFV111 gene is a partially deleted ORFV111 gene.
- the partially deleted ORFV111 gene lacks one or more but not all bases of the ORFV111 gene.
- the partially deleted ORFV111 gene lacks one or more bases of the 3' untranslated region, the coding region and/or the 5' untranslated region, or any combination thereof.
- the partially deleted ORFV111 gene is a 3'-deleted ORFV111 gene, that is, one or more bases at the 3' end are deleted, eg, the entire or part of the 3' untranslated region is deleted, the entire 3' untranslated region is deleted and all or part of the coding region, or deletion of the entire 3' untranslated region, the entire coding region and all or part of the 5' untranslated region.
- the ORFV111 gene is deleted downstream (into the ORFV111/112 intergenic region, if present, and/or the ORFV112 gene, particularly the 5' end) and/or upstream (into the ORFV110/111 intergenic region, if If present, and/or the ORFV110 gene, especially the 3' end) extension.
- the partially deleted ORFV111 gene lacks SEQ ID NO: 59 One or more bases of the sequence set forth in ID NO: 59, eg, 1-793 bases.
- the native ORFV111 gene has or comprises or (essentially) consists of the nucleotide sequence shown in SEQ ID NO: 59 (or its coding region)
- the 3'-deleted ORFV111 gene One or more bases at the 3' end of the sequence shown in SEQ ID NO: 59 are deleted, particularly 1-793, 1-309 or 310-792 bases at the 3' end.
- the 3'-deleted ORFV111 gene has or comprises, or (essentially) consists of, the nucleotide sequence set forth in SEQ ID NO:60 (or its coding region).
- the native ORFV111 gene has or comprises or (essentially) consists of the nucleotide sequence shown in SEQ ID NO: 73-84 (or its coding region)
- the 3'-terminal deletion type The ORFV111 gene deletes one or more bases at the 3' end of the sequences shown in SEQ ID NOs: 73-84, especially one or more bases in the segment corresponding to the 309 bases at the 3' end of SEQ ID NO: 59 base. These deleted genes may not express protein due to the deletion of the 3' untranslated region.
- the mutant ORFV111 gene of the invention results in reduced or absent functional hypothetical protein 111, including reduced or absent expression and/or activity of hypothetical protein 111.
- a reduction is at least a 50%, 60%, 70%, 75%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96% reduction compared to native function and/or expression , 97%, 98%, 99%, up to 100%.
- the present invention relates to an ORFV virus genome.
- the ORFV viral genome has the ORFV112 gene and/or ORFV111 gene described above, including native ORFV112 gene and/or ORFV111 gene and mutant ORFV112 gene and/or ORFV111 gene.
- the present invention relates to an ORFV virus genome deficient in the ORFV112 gene and/or the ORFV111 gene.
- the ORFV112 gene and/or ORFV111 gene-deficient ORFV virus genome comprises the mutant ORFV112 gene and/or ORFV111 gene described above.
- the ORFV viral genome (eg, ORFV112 gene and/or ORFV111 gene-deficient ORFV viral genome) is completely deficient in the ORFV007 gene.
- the 3' non-coding region of the ORFV111 gene coincides with the 5' non-coding region of the ORFV112 gene.
- the present invention relates to an ORFV virus.
- the ORFV virus has the CBP protein and/or hypothetical protein 111 described above, including native CBP protein and/or hypothetical protein 111 and mutant CBP protein and/or hypothetical protein 111.
- the present invention relates to a CBP protein and/or hypothetical protein 111-deficient ORFV virus.
- the CBP protein and/or the hypothetical protein 111 deficient ORFV virus has reduced or deleted functional CBP protein and/or the hypothetical protein 111.
- the reduction or deletion of functional CBP protein and/or hypothetical protein 111 can be a reduction or deletion of the expression and/or activity of the CBP protein and/or hypothetical protein 111.
- the present invention relates to an ORFV virus.
- the ORFV virus has the ORFV112 gene and/or ORFV111 gene described above, including native ORFV112 gene and/or ORFV111 gene and mutant ORFV112 gene and/or ORFV111 gene.
- the ORFV virus has the ORFV virus genome described above, including the ORFV112 gene and/or ORFV111 gene-deficient ORFV virus genome.
- the present invention relates to a CBP protein and/or hypothetical protein 111-deficient ORFV virus comprising the above-mentioned mutant ORFV112 gene and/or ORFV111 gene or the above-mentioned ORFV112 gene and/or ORFV111 gene-deficient ORFV virus Genome.
- an ORFV virus eg, a CBP protein and/or a hypothetical protein 111-deficient ORFV virus
- the present invention relates to a method for modifying ORFV virus genome or ORFV virus.
- the method comprises mutating the ORFV112 gene and/or the ORFV111 gene in the ORFV viral genome.
- the method comprises addition, deletion or substitution, in particular deletion of one or more bases of the ORFV112 gene and/or ORFV111 gene, in particular one or more bases of the 5' end of the ORFV112 gene and/or ORFV111 One or more bases at the 3' end of a gene.
- the method comprises deleting SEQ ID NO: : One or more bases of the sequence shown in 3, eg, 1-1162 bases.
- the method comprises deleting SEQ ID NO: : one or more bases at the 5' end of the sequence shown in 3, especially 1-1161, 1-1140, 1-538, 539-1139 or 1141-1160 bases at the 5' end, such as 538 or 1140 bases.
- the method comprises deleting SEQ ID in its entirety NO:3 or delete the 1140 or 538 5' end bases of SEQ ID NO:3.
- the method comprises deleting said nucleotide sequences entirely or deleting all The segment corresponding to the 1140 or 538 5' end bases of SEQ ID NO: 3 in the nucleotide sequence.
- the method comprises deleting SEQ ID NO: 59 : one or more bases of the sequence shown in 59, eg, 1-794 bases.
- the method comprises deleting SEQ ID NO: 59 : one or more bases at the 3' end of the sequence shown in 59, particularly 1-793, 1-309 or 310-792 bases, eg, 309 bases, at the 3' end.
- the method comprises deleting SEQ ID in its entirety NO:59 or delete the 309 3' terminal bases of SEQ ID NO:59.
- the method comprises deleting said nucleotide sequences entirely or deleting all The segment corresponding to the 309 3'-terminal bases of SEQ ID NO: 59 in the nucleotide sequence.
- the method comprises the complete deletion of SEQ ID NO: 3 and SEQ ID NO:59. In one embodiment, the method further comprises mutating (eg, deletion, including complete deletion or partial deletion) of the ORFV007 gene in the ORFV virus genome, particularly the ORFV112 gene and/or ORFV111 gene-deficient ORFV virus genome. In one embodiment, the 3' non-coding region of the ORFV111 gene coincides with the 5' non-coding region of the ORFV112 gene.
- the methods of the present invention can be performed by conventional molecular biology techniques (eg molecular cloning, DNA recombination, homologous recombination, PCR, restriction nucleases, gene knockout, silencing, etc.) or emerging molecular biology techniques (eg gene editing, etc.) .
- the present invention relates to ORFV virus genomes (eg ORFV112 gene and/or ORFV111 gene-deficient ORFV virus genomes) and ORFV viruses (eg CBP protein and/or hypothetical protein 111-deficient ORFV virus) obtained by the method.
- the present invention relates to a method for identifying ORFV virus genome or ORFV virus, in particular for detecting (presence or activity) and/or genes of CBP protein and/or hypothetical protein 111 (especially mutant CBP protein and/or hypothetical protein 111) Methods for the (presence or sequence) of ORFV112 and/or ORFV111 genes, especially mutant ORFV112 genes and/or ORFV111 genes.
- the methods of the present invention can be performed by conventional molecular biology techniques (eg, activity assays, hybridization (eg, Southern, Northern, or Western)), which detect the presence and/or activity of proteins and/or nucleic acids and/or sequences, Restriction nucleases, PCR, electrophoresis (eg, gel electrophoresis, including protein electrophoresis and nucleic acid electrophoresis, including agarose electrophoresis and PAGE electrophoresis, including reducing and non-reducing electrophoresis), sequencing (including protein sequencing and nucleic acid sequencing), etc.) or Emerging molecular biology techniques such as next-generation sequencing, etc.
- molecular biology techniques eg, activity assays, hybridization (eg, Southern, Northern, or Western)
- electrophoresis eg, gel electrophoresis, including protein electrophoresis and nucleic acid electrophoresis, including agarose electrophoresis and PAGE electrophoresis, including
- the present invention provides methods for detecting the integrity (or length) of the genes ORFV112 and/or ORFV111.
- the method is performed by PCR and gel electrophoresis.
- the method can be performed by nucleic acid hybridization or sequencing.
- the target region of the upstream primer can be, but is not limited to, be positioned at the 5' end of the gene ORFV112 or extend upstream, such as into the ORFV111/112 intergenic region, if any, or
- the gene ORFV111 (especially the 3' end of the gene ORFV111, such as the 3' untranslated region);
- the target region of the downstream primer can be set at the 3' end of the gene ORFV112 or extended downstream, such as into the ORFV112/113 intergene region, if any, or the gene ORFV113 (especially the 5' end of the gene ORFV113, eg, the 5' untranslated region).
- primer/probe targets can be designed based on similar principles.
- the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising a certain amount, particularly an effective amount, such as a therapeutically effective amount or a prophylactically effective amount, of the ORFV virus genome of the present invention (for example, ORFV112 gene and/or ORFV111 gene-deficient ORFV virus genome) and /or ORFV virus (eg CBP protein and/or hypothetical protein 111 deficient ORFV virus).
- the composition comprises a pharmaceutically acceptable carrier.
- the composition is in the form of a powder, solution, transdermal patch, ointment, or suppository.
- the composition is administered by intravenous, intratumoral, intramuscular, subcutaneous, rectal, vaginal or intraperitoneal routes.
- the present invention relates to a method of treating a disease or delaying disease progression in a subject, comprising administering an amount, particularly an effective amount, such as a therapeutically effective amount or a prophylactically effective amount, of an ORFV viral genome of the present invention (such as the ORFV112 gene and /or ORFV111 gene-deficient ORFV virus genome) and/or ORFV virus (eg CBP protein and/or hypothetical protein 111-deficient ORFV virus).
- an ORFV viral genome of the present invention such as the ORFV112 gene and /or ORFV111 gene-deficient ORFV virus genome
- ORFV virus eg CBP protein and/or hypothetical protein 111-deficient ORFV virus
- the present invention relates to an amount, in particular an effective amount, such as a therapeutically effective amount or a prophylactically effective amount, of an ORFV virus genome (eg ORFV112 gene and/or ORFV111 gene-deficient ORFV virus genome) and/or ORFV virus (eg CBP protein) of the present invention and/or hypothetical protein 111-deficient ORFV virus) in the preparation of medicaments.
- an ORFV virus genome eg ORFV112 gene and/or ORFV111 gene-deficient ORFV virus genome
- ORFV virus eg CBP protein
- the present invention relates to an amount, in particular an effective amount, such as a therapeutically effective amount or a prophylactically effective amount, of an ORFV virus genome (eg ORFV112 gene and/or ORFV111 gene-deficient ORFV virus genome) and/or ORFV virus (eg CBP protein) of the present invention and/or hypothetical protein 111-deficient ORFV virus) for use in treating disease or delaying disease progression in a subject.
- an ORFV virus genome eg ORFV112 gene and/or ORFV111 gene-deficient ORFV virus genome
- ORFV virus eg CBP protein
- the disease is cancer.
- the cancer is a solid tumor.
- the solid tumor is cervical cancer, bladder cancer, liver cancer, ovarian cancer, melanoma, colorectal cancer, lung cancer, breast cancer, stomach cancer, uterine cancer, head and neck cancer, thyroid cancer, esophageal cancer, prostate cancer , pancreatic cancer, sarcoma, brain tumor, etc.
- the subject is a mammal, including rodents (eg, mice and rats), non-human primates (eg, cynomolgus monkeys), and humans.
- rodents eg, mice and rats
- non-human primates eg, cynomolgus monkeys
- Example 1 Screening and purification method of mutant sheep infectious pustular dermatitis virus
- the sorted 96-well plate was transferred to a carbon dioxide incubator (Thermo, 160i) at 37°C with a concentration of 5% CO 2 for cultivation. Observe the virus infection every day;
- the PCR product was subjected to Sanger Sequencing (Suzhou Jinweizhi Biotechnology Co., Ltd.), and it was confirmed that the ORFV112 gene encoding of POV-601-1A1 has 538 bases missing at the 5' end, including 226 non-coding 5' ends. bases and 312 bases of the 5' end of the ORFV112 protein coding region (see SEQ ID NO:4); while POV-601-3F8 has the complete ORFV112 gene sequence (see SEQ ID NO:3).
- ⁇ PCR program parameters pre-denaturation at 94°C for 5 min; denaturation at 94°C for 30s, annealing at 62°C for 30s, extension at 68°C for 1 min, 30 cycles; final extension at 68°C for 7min.
- Example 2 Species confirmation of mutant ovine infectious pustular dermatitis virus
- the virus genome was extracted from the POV-601-1A1 strain (Mouse Tail Genomic DNA Kit, Cat#: CW2094S), and sent to a third-party sequencing company for second-generation sequencing (Suzhou Jinweizhi Biotechnology Co., Ltd.). Assemble the sequencing results. After the full sequence of the B2L gene [21] (ORFV011 gene) of the virus strain was searched by BLAST nucleic acid sequence, the one with high similarity to the sequencing result was OV/HLJ/04, with a similarity of 99.91%, confirming the isolated virus strain is ORFV.
- Source of host cell African green monkey kidney cell CV-1 (ATCC No.CCL-70 TM )
- the construction method of recombinant sheep infectious pustular oncolytic virus mainly includes the following steps:
- flanking sequences of the ORFV112 gene (left homology arm and right homology) were cloned by PCR method. arm) and EGFP reporter gene;
- step 3 connecting the PCR product in step 1) with the pUC19 plasmid after digestion to obtain a CBP shuttle plasmid;
- step 4) Take the CBP shuttle plasmid ligation product obtained in step 3) as a template, adopt specific primers (SEQ ID NOs: 13-14) with EcoRI and AgeI restriction endonuclease sites at the ends respectively, and amplify by PCR method , to obtain a linear CBP shuttle vector;
- step 5 Use EcoRI and AgeI to digest the new px330 plasmid vector and px330 plasmid vector backbone (px330 backbone) in step 5), and cut the product by T4 DNA ligase ligase; transform the ligated product into the screening host bacterium DH5 ⁇ to obtain a positive single. Cloning, and expanding the culture, and extracting the plasmid. Sanger sequencing was performed to identify the recombinant plasmid (px330- ⁇ NLS) without nuclear localization signal (NLS);
- step (4) Transfect the obtained px330- ⁇ NLS-CBP gRNA expression plasmid into the selected parapoxvirus host cell CV-1, and then infect the transfected CV-1 cells with POV-601-1A1 virus strain.
- the linear CBP shuttle vector obtained in step (4) was transfected into the px330- ⁇ NLS-CBP gRNA plasmid and the CV-1 cells infected with POV-601-1A1 virus;
- the target cells with EGFP fluorescent virus are collected by enrichment culture, and then sorted and inoculated into a 96-well plate by flow cytometer, and 1 cell is inoculated in each well, and the culture is expanded.
- the target cells were collected from the wells rich in EGFP fluorescent virus, and the viral genomic DNA was extracted and identified by PCR (primers SEQ ID NO: 19-30), and the virus with the target band was re-infected CV-1 cells for expansion culture. ;
- Example 4 Amplification and culture of mutant sheep infectious pustular dermatitis virus
- Source of host cell African green monkey kidney cell CV-1 (ATCC No.CCL-70 TM )
- the virus can be harvested when more than 90% of the virus-infected cells have CPE;
- Example 5 Evaluation of antitumor activity of mutant ovine infectious pustular dermatitis virus in murine bladder cancer tumor model
- mice male C57BL/6 mice, 6W, from Zhejiang Weitong Lihua Laboratory Animal Technology Co., Ltd.
- mice Male C57BL/6 mice were subcutaneously inoculated with MB49 cells resuspended in PBS (Guangzhou Genio Biotechnology Co., Ltd.) at a cell density of 2 ⁇ 10 6 /ml and an inoculation volume of 0.1ml/mice. The day of cell seeding was defined as Day 0. When the average tumor volume in the control group reached about 100 mm 3 , the mice were randomly divided into groups according to the tumor size, and administered according to the description in Table 1. All mice were euthanized on Day 30 after inoculation with cells.
- mice were weighed and tumors were measured twice a week for the entire study.
- the tumor volume was measured using a vernier caliper (model: 16ER; Mahr GmbH). The results are shown in Figure 2.
- Tumor inhibition rate TGI% (1-T/C) ⁇ 100%.
- Example 6 Evaluation of antitumor activity of mutant sheep infectious pustular dermatitis virus in murine melanoma model
- mice Female C57BL/6 mice were subcutaneously inoculated with B16-F10 cells resuspended in PBS (Cell Bank of the Type Culture Collection, Chinese Academy of Sciences) at a cell density of 5 ⁇ 10 6 /ml and an inoculation volume of 0.1ml/ml only. The day of cell injection was defined as Day 0. When the average tumor volume in the control group reached about 100 mm 3 , the mice were randomly divided into groups according to the tumor size, and administered according to the description in Table 3. All mice were comforted on Day 15 after inoculation with cells.
- PBS Cell Bank of the Type Culture Collection, Chinese Academy of Sciences
- mice were weighed and tumors were measured twice a week for the entire study.
- the tumor volume was measured using a vernier caliper (model: 16ER; Mahr GmbH). The results are shown in Figure 3.
- Tumor inhibition rate TGI% (1-T/C) ⁇ 100%.
- s.c. subcutaneous injection
- i.v. tail vein injection
- Test and control articles were injected subcutaneously or tail vein on the right back of female C57BL/6 mice. The date of the first injection was defined as Day 0. Mice were completely randomized and treated according to the description in Table 5. All mice were observed on the 15th day after administration. Mice were weighed daily for the first week and every two to three days thereafter for the entire study.
- mice Body weight changes were monitored in mice. Animal body weights were measured using an ML1602T electronic balance (Mettler). The relative body weight change rate was calculated using the following equation and the results are shown in Figure 4.
- Relative body weight change (%) [weight day new / weight day 0 ] x 100.
- Example 8 Modulating effect of mutant sheep infectious pustular dermatitis virus on immune system
- i.t. intratumoral injection
- i.v. tail vein injection
- mice Female Balb/c-nude mice, 6W, Beijing Huafukang Biotechnology Co., Ltd.
- mice Female Balb/c-nude mice were subcutaneously inoculated with C-33A cells (Cell Bank of the Type Culture Collection, Chinese Academy of Sciences) resuspended in PBS at a cell density of 1 ⁇ 10 8 /ml and an inoculum volume of 0.1 ml/only. The day of cell injection was defined as Day 0. When the average tumor volume reached about 100 mm 3 , the drug treatment was performed according to the description in Table 6. The experiment was terminated 24 hours after the last administration.
- C-33A cells Cell Bank of the Type Culture Collection, Chinese Academy of Sciences
- Example 9 Infectious effect of mutant sheep infectious pustular dermatitis virus on cells in vitro
- Example 8 Evaluation of antitumor activity of mutant ovine infectious pustular dermatitis virus in murine colon cancer model
- CT-26 cells resuspended in PBS were subcutaneously inoculated on the right back of female Balb/c mice at a cell density of 5 ⁇ 10 6 /ml and the inoculum volume was 0.1ml/ml only.
- the day of cell injection was defined as Day 0.
- the mice were randomly divided into groups according to the tumor size, and administered according to the description in Table 8. All mice were comforted on Day 25 after inoculation with cells.
- Tumor inhibition rate TGI% (1-T/C) ⁇ 100%.
- Example 9 Evaluation of antitumor activity of recombinant mutant sheep infectious pustular dermatitis virus in murine melanoma model
- Transmissible pustular dermatitis virus of sheep with complete or partial deletion of the ORFV111 gene and/or ORFV112 gene coding region and/or non-coding region was constructed by recombinant method, and the effect was tested by the method described in Example 6, unless otherwise specified.
- v611a Complete deletion of the ORFV112 gene.
- v615a delete the ORFV111 and ORFV112 coding regions
- v616a Completely remove ORFV111 and ORFV112.
- CTCC China Collection of Type Cultures
- T-VEC talimogene Laherparepvec
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (21)
- 一种突变型羊传染性脓疱皮炎病毒,其特征在于基因ORFV112和/或基因ORFV111的功能性表达产物的缺失。
- 如权利要求1所述的病毒,其中基因ORFV112的功能性表达产物的缺失是由基因ORFV112的完全或部分缺失造成的。
- 如权利要求1所述的病毒,其中基因ORFV111的功能性表达产物的缺失是由基因ORFV111的完全或部分缺失造成的。
- 如权利要求1-3任一项所述的病毒,其中表达产物为蛋白质和/或核酸。
- 一种突变型羊传染性脓疱皮炎病毒,其特征在于基因ORFV112的完全或部分缺失和/或基因ORFV111的完全或部分缺失。
- 一种改造羊传染性脓疱皮炎病毒的方法,其包括降低或消除基因ORFV112的表达产物的表达和/或活性和/或降低或消除基因ORFV111的表达产物的表达和/或活性。
- 如权利要求6所述的方法,其包括完全或部分删除基因ORFV112。
- 如权利要求6所述的方法,其包括完全或部分删除基因ORFV111。
- 如权利要求6-8任一项所述的方法,其中表达为转录和/或翻译。
- 一种改造羊传染性脓疱皮炎病毒的方法,其包括完全或部分删除基因ORFV112和/或完全或部分删除基因ORFV111。
- 通过权利要求6-10任一项的方法得到的病毒。
- 如权利要求1-5和11任一所述的病毒,其中基因ORFV002(NF-κB核抑制剂)、ORFV005(Hypothetical protein)和ORFV007(dUTPase)完全缺失。
- 如权利要求1-5、11和12任一项所述的病毒,其具有复制和溶瘤能力。
- 以CCTCC保藏编号V202029保藏的羊传染性脓疱皮炎病毒。
- 如权利要求1-5和11-14任一项所述的病毒的基因组。
- 一种组合物,其包含如权利要求1-5和11-14任一项所述的病毒和药学上可接受的载剂。
- 如权利要求16所述的组合物,其为粉剂、溶液、透皮贴剂、膏剂、或栓剂的形式。
- 如权利要求16所述的组合物,其通过静脉内、瘤内、肌内、皮下、 经直肠、经***、或腹腔路径来施用。
- 如权利要求1-5和11-14任一项所述的病毒制备用于治疗癌症的药物的用途。
- 如权利要求19所述的用途,其中所述癌症是实体瘤。
- 如权利要求20所述的用途,其中所述实体瘤为***、膀胱癌、肝癌、卵巢癌、黑色素瘤、结直肠癌、肺癌、乳腺癌、胃癌、子宫癌、头颈癌、甲状腺癌、食道癌、***癌、胰腺癌、肉瘤或脑瘤。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202180056444.5A CN116744952A (zh) | 2020-08-13 | 2021-08-13 | 一种突变型羊传染性脓疱皮炎病毒及其用途 |
US18/041,234 US20230340424A1 (en) | 2020-08-13 | 2021-08-13 | Mutant orf viruses and uses thereof |
CA3192853A CA3192853A1 (en) | 2020-08-13 | 2021-08-13 | Mutant orf viruses and uses thereof |
JP2023511666A JP2023537643A (ja) | 2020-08-13 | 2021-08-13 | 突然変異型オルフウイルス及びその使用 |
EP21855623.1A EP4206327A1 (en) | 2020-08-13 | 2021-08-13 | Mutant ovis spp. infectious pustular dermatitis virus and use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010813096 | 2020-08-13 | ||
CN202010813096.9 | 2020-08-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022033573A1 true WO2022033573A1 (zh) | 2022-02-17 |
Family
ID=80247733
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/112408 WO2022033573A1 (zh) | 2020-08-13 | 2021-08-13 | 一种突变型羊传染性脓疱皮炎病毒及其用途 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20230340424A1 (zh) |
EP (1) | EP4206327A1 (zh) |
JP (1) | JP2023537643A (zh) |
CN (1) | CN116744952A (zh) |
CA (1) | CA3192853A1 (zh) |
WO (1) | WO2022033573A1 (zh) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012122649A1 (en) | 2011-03-15 | 2012-09-20 | Ottawa Hospital Research Institute | Recombinant orf virus |
CN103260644A (zh) * | 2010-05-21 | 2013-08-21 | 佐蒂斯有限责任公司 | 含有狂犬病毒抗原的副痘病毒载体 |
CN103952377A (zh) | 2014-04-21 | 2014-07-30 | 中国农业科学院兰州兽医研究所 | 一种用于羊传染性脓疱病毒分离培养和增殖的细胞系及其制备方法和应用 |
CN104017776A (zh) | 2014-04-21 | 2014-09-03 | 中国农业科学院兰州兽医研究所 | 一种羊传染性脓疱病毒细胞弱毒疫苗及其制备方法和应用 |
CN104878043A (zh) | 2015-06-01 | 2015-09-02 | 石河子大学 | 羊口疮病毒毒力基因vir 缺失突变株及其制备方法和应用 |
WO2017165366A1 (en) * | 2016-03-21 | 2017-09-28 | South Dakota Board Of Regents | Orf virus-based platform for vaccine delivery |
CN108026542A (zh) | 2015-07-20 | 2018-05-11 | 蒂宾根大学医学院 | 重组Orf病毒载体 |
CN108220251A (zh) | 2018-02-11 | 2018-06-29 | 南方医科大学 | 一种重组传染性脓疱溶瘤病毒及其制备方法与应用 |
CN108770344A (zh) * | 2016-03-28 | 2018-11-06 | 胡敏杰 | 抗癌溶瘤病毒联合治疗和优良反应者选择平台 |
-
2021
- 2021-08-13 CA CA3192853A patent/CA3192853A1/en active Pending
- 2021-08-13 EP EP21855623.1A patent/EP4206327A1/en active Pending
- 2021-08-13 WO PCT/CN2021/112408 patent/WO2022033573A1/zh active Application Filing
- 2021-08-13 CN CN202180056444.5A patent/CN116744952A/zh active Pending
- 2021-08-13 JP JP2023511666A patent/JP2023537643A/ja active Pending
- 2021-08-13 US US18/041,234 patent/US20230340424A1/en active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103260644A (zh) * | 2010-05-21 | 2013-08-21 | 佐蒂斯有限责任公司 | 含有狂犬病毒抗原的副痘病毒载体 |
WO2012122649A1 (en) | 2011-03-15 | 2012-09-20 | Ottawa Hospital Research Institute | Recombinant orf virus |
CN103952377A (zh) | 2014-04-21 | 2014-07-30 | 中国农业科学院兰州兽医研究所 | 一种用于羊传染性脓疱病毒分离培养和增殖的细胞系及其制备方法和应用 |
CN104017776A (zh) | 2014-04-21 | 2014-09-03 | 中国农业科学院兰州兽医研究所 | 一种羊传染性脓疱病毒细胞弱毒疫苗及其制备方法和应用 |
CN104878043A (zh) | 2015-06-01 | 2015-09-02 | 石河子大学 | 羊口疮病毒毒力基因vir 缺失突变株及其制备方法和应用 |
CN108026542A (zh) | 2015-07-20 | 2018-05-11 | 蒂宾根大学医学院 | 重组Orf病毒载体 |
WO2017165366A1 (en) * | 2016-03-21 | 2017-09-28 | South Dakota Board Of Regents | Orf virus-based platform for vaccine delivery |
CN108770344A (zh) * | 2016-03-28 | 2018-11-06 | 胡敏杰 | 抗癌溶瘤病毒联合治疗和优良反应者选择平台 |
CN108220251A (zh) | 2018-02-11 | 2018-06-29 | 南方医科大学 | 一种重组传染性脓疱溶瘤病毒及其制备方法与应用 |
Non-Patent Citations (23)
Title |
---|
BERGQVIST, CKURBAN, MABBAS, O: "Orf virus infection", REV MED VIROL, vol. 27, no. 4, 2017 |
BURKE, J.NIEVA, JBORAD, M.JBREITBACH, C.J: "Oncolytic viruses: perspectives on clinical development", CURR OPIN VIROL, vol. 13, 2015, pages 55 - 60 |
CDC: "Orf Virus Infection in Humans-New York, Illinois, California, and Tennessee, 2004-2005", MORBIDITY AND MORTALITY WEEKLY REPORT, vol. 55, no. 3, 2006, pages 65 - 68 |
DIEL, D.GLOU, SDELHON, GPENG, YFLORES, E.FROCK, D.L: "A nuclear inhibitor of NF-kappaB encoded by a poxvirus", J VIROL, vol. 85, no. 1, 2011, pages 264 - 275 |
FLEMING STEPHEN B., MCCAUGHAN CATHERINE, LATEEF ZABEEN, DUNN AMY, WISE LYN M., REAL NICOLA C., MERCER ANDREW A.: "Deletion of the Chemokine Binding Protein Gene from the Parapoxvirus Orf Virus Reduces Virulence and Pathogenesis in Sheep", FRONTIERS IN MICROBIOLOGY, vol. 8, 24 January 2017 (2017-01-24), pages 1 - 17, XP055803766, DOI: 10.3389/fmicb.2017.00046 * |
FLEMING, S.B., MCCAUGHAN, C., LATEEF, Z., DUNN, A., WISE, I.M., REAL, N.C., MERCER, A.A: "Deletion of chemokine binding protein gene from the parapoxvirus orf virus reduces virulence and pathogenesis in sheep", FRONT MICROBIOL, vol. 8, 2017, pages 46, XP055803766, DOI: 10.3389/fmicb.2017.00046 |
HANAHAN, DWEINBERG, R.A: "Hallmarks of cancer: the next generation", CELL, vol. 144, no. 5, 2011, pages 646 - 74, XP028185429, DOI: 10.1016/j.cell.2011.02.013 |
HARRINGTON, K.JPUZANOV, IHECHT, J.RHODI, F.SSZABO, ZMURUGAPPAN, SKAUFMAN, H.L: "Clinical development of talimogene Laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy", EXPERT REV ANTICANCER THER, vol. 15, no. 12, 2015, pages 1389 - 1403 |
IRWIN, C.RHITT, M.MEVANS, D.: "Targeting Nucleotide Biosynthesis: A Strategy for Improving the Oncolytic Potential of DNA Viruses", FRONT ONCOL, vol. 7, 2017, pages 229 |
KIRN, D.HTHORNE, S.H: "Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer", NAT REV CANCER, vol. 9, 2009, pages 64 - 71, XP037922459, DOI: 10.1038/nrc2545 |
LIU, WYANG, K.KYIN, D.DWANG, Y.HYU, Z.RJIANG, S.DLI, C.FLI, Y.DWANG, Y: "Prokaryotic expression and subcellular localization of dUTPase gene of orf virus", CHINESE VETERINARY SCIENCE, vol. 7, 2018, pages 818 - 823 |
MCFADDEN, G: "Poxvirus tropism", NAT REV MICROBIOL, vol. 3, no. 3, 2005, pages 201 - 213, XP037065619, DOI: 10.1038/nrmicro1099 |
MIEST, T.SCATTANEO, R: "New viruses for cancer therapy: meeting clinical needs", NAT, vol. 12, no. 1, 2014, pages 23 - 34, XP002768871, DOI: 10.1038/nrmicro3140 |
RINTOUL, J.LLEMAY, C.GTAI, L.HSTANFORD, M.MFALLS, T.JBRIDLE, B.WSOUZA, C.TDANESHMAND, MOHASHI, P.SWAN, Y: "ORFV: a novel oncolytic and immune stimulating parapoxvirus therapeutic", MOL THER, vol. 20, no. 6, 2012, pages 1148 - 1157, XP055730906, DOI: 10.1038/mt.2011.301 |
SEET, B.TMCCAUGHAN, C.A.HANDEL, T.MMERCER, ABRUNETTI, CMCFADDEN, GFLEMING, S.B: "Analysis of an orf virus chemokine-binding protein: shifting ligand specificities among a family of poxvirus viroceptors", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 100, no. 25, 2003, pages 15137 - 15142 |
SEYMOUR, L.WFISHER, K.D: "Oncolytic viruses: finally delivering", BR J CANCER, vol. 114, no. 4, 16 February 2016 (2016-02-16), pages 357 - 361, XP055430570, DOI: 10.1038/bjc.2015.481 |
SON, S.J., HARRIS, P.W., SQUIRE, C.J., BAKER, E.N., KENT, S.B., BRIMBLE, M.A.: "Total Chemical Synthesis of an Orf Virus Protein, ORFV002, an Inhibitor of the Master Gene Regulator NF-KB. Biopolymers", PEPTID SCIENCE, vol. 102, no. 2, 2014, pages 137 - 144, XP071165597, DOI: 10.1002/bip.22445 |
TWUMASI-BOATENG, KJESSICA, L.PEUNICE KWOK, Y.YJOHN, C.BNELSON, B.H: "Oncolytic viruses as engineering platforms for combination immunotherapy", NAT REV CANCER, vol. 18, 2018, pages 419 - 432, XP036530547, DOI: 10.1038/s41568-018-0009-4 |
WANG, G.XSHANG, Y.JCHEN, J.TLU, Z.LZHANG, K.SLIU, X.T: "Isolation and identification of orf virus in Hubei Province", ADVANCES IN ANIMAL MEDICINE, vol. 033, no. 011, 2012, pages 37 - 40 |
WANG, R., WANG, Y., LIU, F., LUO, S.: "Orf virus: A promising new therapeutic agent.", REV MED VIROL, 2013 |
WANG, Z.J: "Science Press", 2018, article "Research, development and quality control of Biopharmaceuticals" |
YAN FENG-CHAO , SHAO JIA , GOU YONG-XI: "Progress in Molecular Biology of Orf Virus", CHINESE VETERINARY SCIENCE, vol. 43, no. 1, 20 January 2013 (2013-01-20), pages 103 - 109, XP055901354, DOI: 10.16656/j.issn.1673-4696.2013.01.009 * |
YIN, ZLIU, J.H: "Animal Virology", 1997, SCIENCE PRESS, pages: 977 - 978 |
Also Published As
Publication number | Publication date |
---|---|
EP4206327A1 (en) | 2023-07-05 |
US20230340424A1 (en) | 2023-10-26 |
JP2023537643A (ja) | 2023-09-04 |
CN116744952A (zh) | 2023-09-12 |
CA3192853A1 (en) | 2022-02-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102227180B1 (ko) | 재조합 헤르페스 심플렉스 바이러스 및 이의 용도 | |
JP6794442B2 (ja) | 新規な遺伝子組換えワクシニアウイルス | |
JP5783642B2 (ja) | Mvaの主なゲノム欠失を含むワクシニアウイルス変異体 | |
WO2019080537A1 (zh) | 包含溶瘤病毒和car-nk细胞的治疗剂及应用、药盒、***和/或癌症的方法 | |
WO2020239040A1 (zh) | 重组溶瘤病毒以及制备方法、应用和药物 | |
CN108220251B (zh) | 一种重组传染性脓疱溶瘤病毒及其制备方法与应用 | |
Reddy et al. | Cloning of a very virulent plus, 686 strain of Marek's disease virus as a bacterial artificial chromosome | |
Sun et al. | Lorf9 deletion significantly eliminated lymphoid organ atrophy induced by meq-deleted very virulent Marek’s disease virus | |
CN113832115A (zh) | 融合基因ril-7联合ccl19重组溶瘤牛痘病毒及其在制备抗肿瘤药物中的应用 | |
WO2024012483A1 (zh) | 一种基因缺失的减毒非洲猪瘟病毒毒株及其构建方法和应用 | |
WO2022033573A1 (zh) | 一种突变型羊传染性脓疱皮炎病毒及其用途 | |
JP2017515806A (ja) | ポックスウイルス腫瘍細胞崩壊性ベクター | |
CN114657154B (zh) | 一种羊传染性脓疱病毒减毒株的制备方法及其应用 | |
WO2020230785A1 (ja) | 細胞融合を誘導するワクシニアウイルス及びその利用 | |
WO2023016572A1 (zh) | 经修饰的痘苗病毒及其应用 | |
JP6915792B1 (ja) | 広範囲遺伝子欠損を有する腫瘍溶解性ワクシニアウイルス | |
WO2022107705A1 (ja) | 新規遺伝子組換えワクシニアウイルス及びその利用 | |
CN112522215B (zh) | 一种缺失008基因的重组羊口疮病毒及其构建方法 | |
WO2016062226A1 (zh) | 复制型痘苗病毒载体艾滋病疫苗 | |
JP7274138B2 (ja) | Scr欠失ワクシニアウイルス | |
CN108220252B (zh) | 一种传染性脾肾坏死病毒orf022基因缺失株及其制备方法和应用 | |
CN113846068A (zh) | 融合基因ril-7重组牛痘病毒及其在制备抗肿瘤药物中的应用 | |
CN117247910A (zh) | 重组溶瘤痘苗病毒及其应用 | |
CN112481222A (zh) | 一种条件复制型重组单纯疱疹病毒、疫苗及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21855623 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202180056444.5 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 2023511666 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 3192853 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2021855623 Country of ref document: EP Effective date: 20230313 |